elililly
German Chancellor Olaf Scholz sees the strengthening of Germany as a centre for pharmaceuticals as a main task of the federal government. "Whatever we can do as a federal government to strengthen Germany as a pharmaceutical location, we will do," Scholz said on Monday at the symbolic ground-breaking ceremony for a new plant of the US pharmaceutical company Eli Lilly in Alzey in the western German state of Rhineland-Palatinate. The US company is investing around €2.3 billion ($2.5 billion) in the site near Worms. "We are talking about one of, if not the largest single investment in Germany as a...
DPA Breaking News
Bundeskanzler Olaf Scholz (SPD) sieht die Stärkung des Pharmastandorts Deutschland als wichtige Aufgabe für die Bundesregierung. «Was immer wir als Bund tun können, um den Pharmastandort Deutschland zu stärken, das werden wir tun», sagte Scholz beim symbolischen Spatenstich für ein neues Werk des US-Pharmakonzerns Eli Lilly im rheinland-pfälzischen Alzey. Der US-Konzern investiert rund 2,3 Milliarden Euro in den Standort in Rheinhessen. «Wir reden über eine, wenn nicht die größte Einzelinvestition in den Pharmastandort Deutschland seit der Wiedervereinigung», sagte Scholz. Eli Lilly baut in Al...
DPA (German)
Washington (AFP) - Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder. Donanemab has been found to slow cognitive decline in the early stages of the disease during a clinical trial -- but there was also a high rate of side effects, including deaths. The Food and Drug Administration (FDA) "has informed Lilly it wants to further understand topics related to evaluating the safety and efficacy of donanemab," the company said in a statement Friday. Th...
AFP
US company Jazz Pharmaceuticals announced Wednesday the appointment of Philip Johnson as Executive Vice President and Chief Financial Officer, effective March 1. Johnson succeeds Renee Gala, who was promoted to President and Chief Operating Officer in October 2023. In his new role, he will oversee financial reporting, accounting, tax, treasury, risk management, financial planning and analysis, information services and facilities. He will also oversee the company's investor relations and corporate development functions. Johnson, who holds over 35 years of financial experience, spent nearly thre...
DPA Breaking News
Washington (AFP) - The US Food and Drug Administration (FDA) on Wednesday announced it had approved Eli Lilly's highly anticipated weight loss drug Zepbound, the latest entrant in a field of powerful -- and lucrative -- new obesity medicines. It is expected to be available in the United States within weeks, joining the likes of Novo Nordisk's successful Ozempic and Wegovy, and is widely expected to become a bestseller. JPMorgan analysts have predicted annual sales for so-called GLP-1 drugs to reach $140 billion by 2032, with the market dominated by Novo and Lilly. Administered by weekly injec...
AFP
CNBC transcript: Eli Lilly And Co (NYSE:LLY) Chairman & CEO David Ricks speaks with Meg Tirrell live during CNBC’s Healthy Returns Summit today Q1 2021 hedge fund letters, conferences and more WHEN: Today, Tuesday, May 11 WHERE: CNBC’s “Healthy Returns Summit: New Era of Innovation” CNBC's Interview With Eli Lilly CEO David RicksTYLER MATHISEN: More than six million Americans have Alzheimer's disease, and that number predicted to escalate more than double by 2015, yet the FDA has not approved a new drug to treat the disease since 2003. Our next guest is hoping to change that. David Ricks is th...
ValueWalk
Commenting on Eli Lilly’s antibody treatment being halted and today’s trading, Gorilla Trades strategist Ken Berman said:Q3 2020 hedge fund letters, conferences and moreEli Lilly's Antibody Treatment HaltedThe major indices are mixed and flat at midday following a choppy and nervous morning session on Wall Street. The financial sector was in focus with regards to earrings for the second day in a row this morning and today’s reports were much weaker than yesterday’s ones. Bank of America (BAC, -4.1%) missed on its top line, while Wells Fargo (WFC, -5.0%) reported bearish earnings, with only Gol...
ValueWalk
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら